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Glioblastoma multiforme (GBM) carries a dismal prognosis despite the current standard of multimodality treatments. Recent
studies showed promising results to a regimen consisting of a VEGF inhibitor, (bevacizumab) and a topoisomerase I inhibitor
(irinotecan) [BI] in recurrent GBM. However, those patients with GBM who progress on BI will succumb to their disease generally
in a very short period of time. We report a case of a 56-year-old male patient with GBM who declined surgical resection
and received chemoradiation with temozolomide. This treatment was withheld secondary to signiﬁcant thrombocytopenia.
Subsequently,heachievedstablediseasefor10monthswitharegimenconsistingofthalidomideandtamoxifenbeforeprogressing.
This was followed by bevacizumab with irinotecan [BI], for which he had a signiﬁcant partial response for 8 months with
subsequent progression. Reinducing the patient with bevacizumab in combination with a pegylated liposomal doxorubicin
[PLD] (a topoisomerase II inhibitor) demonstrated antitumor activity with signiﬁcant shrinkage of contrast enhancing mass and
peritumoral edema.
Copyright © 2008 Mohammed Almubarak et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Glioblastoma multiforme (GBM) is the most common
primarybraintumorinadults.Despiteadvancementinareas
of clinical detection and treatment, GBM continues to have
an ominous prognosis with median survival less than a year
[1]. Historically,GBM wastreatedwithresection followed by
radiation. The addition of nitrosourea-based chemotherapy
addedasmallsurvivalbeneﬁt.Thestandardoftreatmentwas
c h a n g e da f t e rS t u p pe ta l .[ 2] demonstrated an improvement
in survival by 2 months using temozolomide in combination
with radiation compared to radiation alone.
Bevacizumab is a recombinant humanized monoclonal
antibody that inhibits the biologic activity of vascular
endothelial growth factor (VEGF). GBM is a highly vascular-
izedtumorwithahighexpressionofVEGF[3].Bevacizumab
has shown promising results in a recent phase II clinical trial
when combined with a topoisomerase I inhibitor, irinotecan,
for the treatment of recurrent GBM [4]. The antitumor
activity of bevacizumab containing regimens could be due
to enhanced permeability of the tumor vasculature which
leads to improved penetration of the cytotoxic chemother-
apy agents. We hypothesized that replacing irinotecan
with another cytotoxic chemotherapy agent with a diﬀer-
enet resistance proﬁle may overcome the resistance to BI
regimen.
PLD is a liposome-encapsulated dosage form of doxoru-
bicin which works by intercalating into DNA resulting in
inhibition of DNA synthesis. It also inhibits topoisomerase
II [5]. PLD has several potential advantages over standard
doxorubicin including longer circulatory half-life, more
speciﬁc delivery to tumor tissue and reduced cardiac toxicity
[6]. A cross-resistance between irinotecan and PLD to
our knowledge has not been described. Combining PLD
with bevacizumab might prove to be eﬀective in treating
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Figure 1: MRI brain T1 with gadolinium after stopping bevacizumab with irinotecan.
2.CaseReport
A 56-year-old healthy man presented in October 2004 with
short-term memory deﬁcit and a left-sided visual ﬁeld
defect. A magnetic resonance image (MRI) of the brain
showed a large (5.7cm × 3.5cm) right occipitoparietal
enhancing mass with extension into the ventricular system
and satellite metastases with associated edema and mass
eﬀect.He underwent a stereotactic biopsy of the lesion
that revealed a diagnosis of GBM. The patient declined
surgical resection. He received steroids and was placed on
levetiracetam (Keppra, UCB Inc., Smyrna, Ga, USA) for
seizure prophylaxis.
The patient was started on concomitant chemoradio-
therapy per Stupp regimen consisting of temozolomide
(Temodar, Schering Corporation, Kenilworth, NJ, USA)
75mg/m2 daily as well as radiation therapy (a total of 59.4
Gy). He had signiﬁcant improvement in his neurological
function with evidence of partial response on brain MRI.
However, temozolomide had to be discontinued after
2 months secondary to severe thrombocytopenia. After
completion of the radiation therapy, he was then started
on thalidomide 300mg and tamoxifen 200mg daily for
maintenance. His disease was stable on this regimen
for approximately 10 months. Subsequently, a brain
MRI showed progression of disease. This regimen was
discontinued and he was started on bevacizumab (Avastin,
Genentech Inc., South San Francisco, Calif, USA) 10mg/kg
with irinotecan 125mg/m2 every 2weeks based on an
abstract published by Stark-Vance in 2005 [7]. He had a
90 percent decrease in the tumor size after two cycles on
this regimen. However, after seven cycles on this regimen
a brain MRI showed increased mass eﬀect and interval
development of abnormal contrast enhancement in the
medial hemispheric aspect of the right occipital and parietal
lobe area, compatible with progression of disease (Figure 1).
Subsequently, he was restarted on temozolomide
150mg/m2 on days 1–5 every month. He developed
neutropenia requiring growth factor support as well as
thrombocytopenia requiring oprelvekin (Neumega, Wyeth
Pharmaceuticals Inc., Philadelphia, Pa). After 2 cycles on
this regimen, his follow-up brain MRI showed progression
of disease (Figure 2). He was not considered a candidate
for additional alkylating agent-based chemotherapy such
as carmustine (BCNU) or the PCV regimen (procarbazine,
lomustine, vincristine) due to dose limiting hematologic
toxicity experienced with temozolomide.
The patient was reinduced with bevacizumab 10mg/kg
with the addition of pegylated liposomal doxorubicin
(Doxil, Ortho Biotech Products, LP, Bridgewater, NJ, USA)
20mg/m2 every 2 weeks. His brain MRI (T1 with gadolin-
ium, FLAIR and T2 weighted images) after 4 treatments
showed substantial decrease in bulk of the large mass in the
right posterior cerebral hemisphere with associated decrease
in edema (Figure 3).
Despite achieving the dramatic imaging response and
initial improvement in performance status, the patient
declined further chemotherapy and imaging modalities. He
developed decubitus ulcer and died 2 months after he
received his last dose of PLD/bevacizumab.
Table 1 summarizesthetreatmentregimensandduration
of response for this patient.
3. Discussion
GBM is a highly vascularized tumor and thus target-
ing angiogenesis could represent a major new treatment
approach. Ahmed et al. demonstrated 64% (or 9 out of
14 patients) response/disease stabilization lasting anywhere
from 8 to 135 weeks using an outpatient oral regimen of
the angiogenesis inhibitor, thalidomide, plus tamoxifen, and
temozolomide [8].
VEGF inhibitors are currently being investigated in
several clinical trials. An abstract published by Stark-Vance
at the sixth meeting of the European Association of Neuro-
oncology showed 43% response (9 out of 21 patients) to a
regimen consisting of bevacizumab and irinotecan every 2
weeks [7]. Vredenburgh et al. further conﬁrmed the eﬃcacy
of irinotecan and bevacizumab in patients with recurrent
grade III-IV gliomas. In this phase II trial, 57% out of the
35 patients had radiographic response and the 6-month
overall survival was 77%. Of note, four patients developed
thomboembolic complications and one had a CNS bleed
[4]. Based on this data, the National Cancer ComprehensiveJournal of Oncology 3
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Figure 2: Brain T1 with gadolinium prior to reinduction with bevacizumab with PLD.
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Figure 3: Brain T1 with gadolinium after treatment with bevacizumab with PLD.
Network (NCCN) has updated their guidelines recently to
include bevacizumab-based regimens as a salvage treatment
option in recurrent GBM [9].
Since VEGF inhibitors aﬀect the vascular permeability
of the tumor, this may result in decrease in contrast
enhancement in MRI images [10]. This might lead to
questioning the true validity of using MRI to assess response
to treatment. Pope et al. evaluated MRI response in high-
grade gliomas treated with bevacizumab in addition to
diﬀerent chemotherapeutic agents. They noted reduction in
contrastenhancingtumorin7outof14patientsinaslittleas
2 weeks. Of interest, even in those patients who did not have
reductionintumorssize,areductioninedemawasnoted[3].
Nonetheless, response to such bevacizumab containing
regimen in high-grade gliomas was proved using positron
emission tomography (PET) by Chen et al. In this study, a
47% response rate (9 out of 19) was reported with 65% 6-
month survival. Metabolic responders survived three times
as long as nonresponders (10.8 versus 3.4 months). This was
the ﬁrst study to describe the ability to use PET scan as
an imaging modality for predicting survival in patients who
were treated with bevacizumab [11].
Irinotecan is a water soluble camptothecin (CPT) analog
that interferes with the catalytic cycle of topoisomerase I
enzyme. Irinotecan as a single agent has very low response
rate in GBM [12]. The signiﬁcant response noted when
combined with bevacizumab could be due to improved
drug delivery resulting from a reduction in interstitial
ﬂuid pressure and normalization of the tumor vasculature
by bevacizumab [13]. This introduces the possibility of
enhanced blood brain barrier (BBB) penetration of other
cytotoxic agents when combined with bevacizumab.
Doxorubicin has shown signiﬁcant in vitro cytotoxicity
in cell lines derived from malignant glioma cells [14].
Unfortunately, doxorubicin does not adequately penetrate
the BBB [15] and is subject to resistance due to P-
glycoprotein mediated eﬄux [16, 17]. However, pegylated
liposomal doxorubicin selectively overcomes the BBB in the
tumor areas, with accumulation more than 10 fold higher in
the tumor than in normal brain tissue [18]. Pegylated lipo-
somal doxorubicin also appears to overcome P-glycoprotein
mediated resistance [19]. Moreover, there seems to be an
enhanced drug exposure and improvement in therapeutic
activitywhencomparingpegylatedliposomaldoxorubicinto
conventional doxorubicin in brain tumors in rats [20].
A single agent regimen with pegylated liposomal dox-
orubicin has proven moderate eﬃcacy in GBM patients
as demonstrated by Fabel et al. who observed disease4 Journal of Oncology
Table 1:Summaryoftreatmentregimensanddurationofresponse.
Chemotherapy/treatment Response
(1) Temozolomide and
radiation
Partial response after two
months, but discontinued
secondary to signiﬁcant
thrombocytopenia.
(2) Thalidomide and
tamoxifen
Disease stabilization for 10
months with subsequent
progression.
(3) Bevacizumab with
irinotecan
Signiﬁcant partial response for 8
months with subsequent
progression.
(4) Temozolomide
reinduction
Disease progression after 2
months.
(5) Bevacizumab
reinduction and pegylated
liposomal doxorubicin
Partial response (approximately
60%) after 2 months. Treatment
stopped at the patient’s request.
stabilization in 7 of 13 patients (54%) treated with PLD
20mg/m2 every 2 weeks [21]. Similarly, Hau et al. observed
40% (out of 20 patients) overall response rate and 15% six
months progression-free survival using PLD 20mg/m2 every
2 weeks, either alone or with tamoxifen [22].
In summary, previous studies demonstrated that pegy-
lated liposomal doxorubicin penetrates BBB and achieves
high-level concentration in tumor tissue. The recently
described response to bevacizumab containing regimens
opens the door for combining bevacizumab with other
cytotoxic chemotherapeutic agents. The addition of pegy-
lated liposomal doxorubicin to bevacizumab seems to be a
reasonable alternative in recurrent GBM, as illustrated by
the dramatic response observed in our patient despite heavy
pretreatment. Further studies are needed to evaluate this
regimen as a therapeutic option for treatment of recurrent
or refractory GBM.
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